1 Problem This Pharma Doesn't Want to Talk About

Teva's CEO recently spoke at the JPMorgan Healthcare Conference and offered his view on the company's future. This drugmaker certainly has many future opportunities, but it's also facing the imminent patent expiration of its leading MS drug, Copaxone, a compound that currently accounts for a fifth of the company's revenue.

While Biogen continues to steal the spotlight as its MS drug BG-12 nears an FDA decision, a discussion of the MS market was absent from the conference talk. In this video, Max Macaluso offers an overview of this presentation, compares Teva's profit margins to its generic pharma peers Watson Pharmaceuticals and Mylan , and discusses his outlook for Teva.

What's inside Supernova?
If you're an investor looking for big long-term winners, Motley Fool co-founder David Gardner's picks have frequently trounced the market. How? Because he's always on the lookout for revolutionary stocks and recommends them before Wall Street catches on to their disruptive potential. If you're interested in how David discovers his winners, click here to get instant access to a personal tour behind David's Supernova service.

The article 1 Problem This Pharma Doesn't Want to Talk About originally appeared on Fool.com.

Max Macaluso, Ph.D. has no position in any stocks mentioned. The Motley Fool recommends Momenta Pharmaceuticals. The Motley Fool owns shares of Momenta Pharmaceuticals. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.